NeuBase Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

NeuBase Therapeutics

11/08/2022 14:42

* NeuBase Therapeutics Inc  NBSE.OQ  reported a quarterly
adjusted
loss of 26 cents​​ per share for the quarter ended in June. The
mean expectation of four analysts for the quarter was for a loss
of 30 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * NeuBase Therapeutics Inc's reported EPS for the quarter
was a
loss of 26 cents​.
    * The mean earnings estimate of analysts had fallen by
about 36.9%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * NeuBase Therapeutics Inc shares had risen by 11.4% this
quarter and lost 58.4% so far this year.
    * The company reported a quarterly loss of $8.49 million.
    * Wall Street's median 12-month price target for NeuBase
Therapeutics Inc is $11.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 11
at 01:42 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.30          -0.26          Beat
 Mar. 31 2022      -0.23          -0.30          Missed
 Dec. 31 2021      -0.23          -0.24          Missed
 Sep. 30 2021      -0.23          -0.21          Beat